Press Releases

Promedior to Participate in Panel Discussion at Citi’s 9th Annual Biotech Conference

LEXINGTON, Mass., August 27, 2014 — Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that Suzanne L. Bruhn, Ph.D., President and Chief Executive Officer, will participate in a panel discussion entitled “Anti-Fibrotic Therapies: New Directions for an Old Problem” at the Citi 9th Annual Biotech Conference on Wednesday, September 3, 2014 at 1:00 p.m. EDT at the Mandarin Oriental Hotel in Boston, MA.

About Promedior
Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat rare diseases involving fibrosis. Its proprietary development platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, preventing and potentially reversing fibrosis. PRM-151, the Company’s lead candidate is in a Phase 2 trial for myelofibrosis, and preliminary data demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. PRM-151 has also been tested in idiopathic pulmonary fibrosis, or IPF, and data from a Phase 1b study of PRM-151 in IPF patients resulted in a mean improvement in Forced Vital Capacity at 8 weeks. PRM-151 was well tolerated in both studies. For more information about Promedior, please visit www.promedior.com.

Investor Contact:
Lilian Stern
Stern Investor Relations
+1-212-362-1200
lilian@sternir.com

PTX-2

Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >